EUVIMEDEUVIMED entdecken
Crossref

Hypofractionated Adjuvant Radiation Therapy for Resected Head and Neck Cancers (HART-HN) Allows Safe Dose Condensation to 32.5 Gy in 5 fractions for Intermediate Risk Resected Head and Neck Cancers: Results of a Phase I Trial

M.J. Awan, S. Tarima, A. Banerjee, M.E. Shukla, S. Firat, B. Massey, K. Akakpo, J. Bruening, C.J. Schultz, S. Wong, J. Zenga

International Journal of Radiation Oncology*Biology*Physics · 2026-05 · 125 (1) · e54-e55

DOI: 10.1016/j.ijrobp.2026.02.107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-05. Verfasst von M.J. Awan und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Awan, M., Tarima, S., Banerjee, A., Shukla, M., Firat, S., Massey, B., Akakpo, K., Bruening, J., Schultz, C., Wong, S., & Zenga, J. (2026). Hypofractionated Adjuvant Radiation Therapy for Resected Head and Neck Cancers (HART-HN) Allows Safe Dose Condensation to 32.5 Gy in 5 fractions for Intermediate Risk Resected Head and Neck Cancers: Results of a Phase I Trial. International Journal of Radiation Oncology*Biology*Physics, 125(1), e54-e55. https://doi.org/10.1016/j.ijrobp.2026.02.107

Vancouver

Awan M, Tarima S, Banerjee A, Shukla M, Firat S, Massey B, et al. Hypofractionated Adjuvant Radiation Therapy for Resected Head and Neck Cancers (HART-HN) Allows Safe Dose Condensation to 32.5 Gy in 5 fractions for Intermediate Risk Resected Head and Neck Cancers: Results of a Phase I Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;125(1):e54-e55. doi:10.1016/j.ijrobp.2026.02.107

BibTeX
@article{Awan2026,
  author = {Awan, M.J. and Tarima, S. and Banerjee, A. and Shukla, M.E. and Firat, S. and Massey, B. and Akakpo, K. and Bruening, J. and Schultz, C.J. and Wong, S. and Zenga, J.},
  title = {Hypofractionated Adjuvant Radiation Therapy for Resected Head and Neck Cancers (HART-HN) Allows Safe Dose Condensation to 32.5 Gy in 5 fractions for Intermediate Risk Resected Head and Neck Cancers: Results of a Phase I Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {125},
  number = {1},
  pages = {e54--e55},
  doi = {10.1016/j.ijrobp.2026.02.107}
}
Kostenlos starten →